BRPI0820960A2 - composição - Google Patents

composição

Info

Publication number
BRPI0820960A2
BRPI0820960A2 BRPI0820960A BRPI0820960A BRPI0820960A2 BR PI0820960 A2 BRPI0820960 A2 BR PI0820960A2 BR PI0820960 A BRPI0820960 A BR PI0820960A BR PI0820960 A BRPI0820960 A BR PI0820960A BR PI0820960 A2 BRPI0820960 A2 BR PI0820960A2
Authority
BR
Brazil
Prior art keywords
composition
Prior art date
Application number
BRPI0820960A
Other languages
English (en)
Inventor
Serra Vicent
Original Assignee
Wittycell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wittycell filed Critical Wittycell
Publication of BRPI0820960A2 publication Critical patent/BRPI0820960A2/pt
Publication of BRPI0820960B1 publication Critical patent/BRPI0820960B1/pt
Publication of BRPI0820960B8 publication Critical patent/BRPI0820960B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/04Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/04Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/06Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical being a hydroxyalkyl group esterified by a fatty acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/04Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06Aminosugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
BRPI0820960A 2007-12-05 2008-12-05 composição, composição farmacêutica, e uso da composição BRPI0820960B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99246007P 2007-12-05 2007-12-05
PCT/IB2008/003945 WO2009101475A2 (en) 2007-12-05 2008-12-05 Compositions for and methods of enhancing the immune response to antigens

Publications (3)

Publication Number Publication Date
BRPI0820960A2 true BRPI0820960A2 (pt) 2017-05-09
BRPI0820960B1 BRPI0820960B1 (pt) 2020-04-07
BRPI0820960B8 BRPI0820960B8 (pt) 2021-05-25

Family

ID=40788916

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820960A BRPI0820960B8 (pt) 2007-12-05 2008-12-05 composição, composição farmacêutica, e uso da composição

Country Status (14)

Country Link
US (2) US8211861B2 (pt)
EP (1) EP2231145B1 (pt)
JP (1) JP5813953B2 (pt)
KR (1) KR101566847B1 (pt)
CN (1) CN101917985B (pt)
AU (1) AU2008350531B2 (pt)
BR (1) BRPI0820960B8 (pt)
CA (1) CA2708246C (pt)
DK (1) DK2231145T3 (pt)
ES (1) ES2525127T3 (pt)
PT (1) PT2231145E (pt)
RU (1) RU2537188C2 (pt)
WO (1) WO2009101475A2 (pt)
ZA (1) ZA201003964B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916164B2 (en) * 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
EP2058011A1 (en) * 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
WO2013162016A1 (ja) 2012-04-26 2013-10-31 独立行政法人理化学研究所 新規カルバメート糖脂質およびその用途
SG11201607484RA (en) 2014-03-13 2016-10-28 Univ Basel Carbohydrate ligands that bind to igm antibodies against myelin-associated glycoprotein
CA2996073A1 (en) * 2015-09-16 2017-03-23 Universitat Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
BR112019004906A2 (pt) 2016-09-14 2019-06-25 Abivax combinação incluindo abx196 para o tratamento de câncer
BR112020004778A2 (pt) * 2017-09-13 2020-10-13 Abivax usos de um composto abx196 e de uma composição farmacêutica
CN110241060B (zh) * 2019-08-02 2020-10-09 青岛农业大学 一种水貂肺炎克雷伯氏菌及其应用
EP4301374A4 (en) 2021-03-01 2025-09-10 Deciduous Therapeutics Inc COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242800A (en) 1990-01-30 1993-09-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Receptor for pathogenic fungi
US5936076A (en) * 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
TW261533B (pt) * 1992-07-16 1995-11-01 Kirin Brewery
AU683026B2 (en) * 1992-10-22 1997-10-30 Kirin Pharma Kabushiki Kaisha Novel shingoglycolipid and use thereof
CA2160566C (en) 1993-04-15 2004-07-13 Tatsuo Higa Novel sphingoglycolipids and uses thereof
WO1994026760A1 (en) * 1993-05-14 1994-11-24 Cytel Corporation SIALYL Lex ANALOGUES AS INHIBITORS OF CELLULAR ADHESION
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
EP0821068A3 (en) * 1996-03-29 1999-06-02 Rohm And Haas Company Novel sphingolipids and a process thereto
ES2221147T3 (es) 1997-02-05 2004-12-16 Kirin Beer Kabushiki Kaisha Composiciones liofilizadas conteniendo glicoesfingolipidos.
US6417167B1 (en) 1997-02-05 2002-07-09 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing shingoglycolipid and process for preparing them
CN1222293C (zh) * 1997-04-10 2005-10-12 麒麟麦酒株式会社 含有α-糖基神经酰胺的NKT细胞活化剂
CA2316041A1 (en) 1997-12-30 1999-07-08 Pam Fredman Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complications
US6610835B1 (en) 1998-02-12 2003-08-26 Emory University Sphingolipid derivatives and their methods of use
WO2001082935A1 (fr) * 2000-04-28 2001-11-08 Orient Cancer Therapy Co.,Ltd. Remedes contre le cancer
JP4410913B2 (ja) 2000-06-12 2010-02-10 壽製薬株式会社 新規糖脂質誘導体の製造方法
AU2001268564A1 (en) * 2000-06-22 2002-01-02 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
AR034413A1 (es) 2000-08-25 2004-02-25 Nestor Abel Chamoles Metodo para determinar la actividad de las enzimas lisosomales
AU2002327338A1 (en) 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
KR100549866B1 (ko) 2001-08-22 2006-02-08 고려대학교 산학협력단 암치료 및 예방 제제
WO2003039568A1 (fr) 2001-11-06 2003-05-15 Orient Cancer Therary Co.,Ltd. Compositions anticancereuses
US7273853B2 (en) 2002-05-13 2007-09-25 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives
AU2003251518B2 (en) 2002-06-13 2009-07-02 New York University Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
US7645873B2 (en) * 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
GB0314682D0 (en) 2003-06-24 2003-07-30 Isis Innovation Materials and methods relating to the modulation of T cell response to soluble antigen
US7771726B2 (en) * 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
AU2005235080A1 (en) 2004-03-31 2005-11-03 New York University Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
AU2005282684B9 (en) 2004-09-03 2011-07-07 Brigham Young University Methods of activating NKT cells
WO2006071848A2 (en) * 2004-12-28 2006-07-06 The Rockefeller University Glycolipids and analogues thereof as antigens for nk t cells
WO2006083671A2 (en) 2005-01-28 2006-08-10 Brigham Young University Bacterial glycolipid activation of cd1d-restricted nkt cells
KR100764678B1 (ko) * 2005-07-13 2007-10-09 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물
EP1776963A1 (en) * 2005-10-19 2007-04-25 Gbf-Gesellschaft Für Biotechnologische Forschung Mbh Hexosylceramides as adjuvants and their uses in pharmaceutical compositions
US8039670B2 (en) 2005-10-25 2011-10-18 Ludwig Institute For Cancer Research Analogs of alpha galactosyceramide and uses thereof
SI2056842T1 (sl) * 2006-04-07 2013-02-28 The Scripps Research Institute Modificiran galaktosil-ceramid za zdravljenje kancerogenih obolenj
BRPI0621599B1 (pt) 2006-04-27 2021-07-27 Cellid Co., Ltd Vacina baseada em células b carregadas com o ligante da célula t exterminadora natural e antígeno
AU2007269299B2 (en) 2006-06-30 2013-01-17 Brigham Young University Adjuvants and methods of use
EP1938836A1 (en) 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Compositions comprising a B subunit of shiga toxin and a means stimulating NKT cells
KR100868959B1 (ko) 2006-12-30 2008-11-17 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는면역보조용 약학적 조성물
US8916164B2 (en) 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
EP2058011A1 (en) 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
CN102215864A (zh) 2008-10-08 2011-10-12 威蒂赛尔公司 用于抗流感的疫苗组合物

Also Published As

Publication number Publication date
KR101566847B1 (ko) 2015-11-06
ZA201003964B (en) 2011-02-23
RU2537188C2 (ru) 2014-12-27
DK2231145T3 (en) 2014-12-08
CA2708246C (en) 2016-05-24
WO2009101475A2 (en) 2009-08-20
CN101917985B (zh) 2014-07-02
US20100322952A1 (en) 2010-12-23
CA2708246A1 (en) 2009-08-20
WO2009101475A3 (en) 2009-10-22
KR20100094556A (ko) 2010-08-26
US20090162385A1 (en) 2009-06-25
AU2008350531A1 (en) 2009-08-20
BRPI0820960B8 (pt) 2021-05-25
BRPI0820960B1 (pt) 2020-04-07
US8211861B2 (en) 2012-07-03
US8207135B2 (en) 2012-06-26
EP2231145A2 (en) 2010-09-29
JP2011506306A (ja) 2011-03-03
JP5813953B2 (ja) 2015-11-17
CN101917985A (zh) 2010-12-15
PT2231145E (pt) 2014-12-23
EP2231145B1 (en) 2014-09-17
ES2525127T3 (es) 2014-12-17
RU2010127339A (ru) 2012-01-10
AU2008350531B2 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
BRPI0813775A2 (pt) Composição
ATE528048T1 (de) Schweisshemmende/desodorierende zusammensetzung
ME01423B (me) Fungicidni sastavi
BRPI0906749A2 (pt) Composição
BRPI0913808A2 (pt) composição
BRPI0716325A2 (pt) Composição antimicrobianas
EP2170350A4 (en) SUBSTITUTED IMIDAZOHETEROCYCLES
ATE542825T1 (de) Substituierte piperidino-dihydrothienopyrimidine
DE602008002756D1 (de) Bauzusammensetzung
EP2381760A4 (en) CORN PROTEIN COMPOSITION
ATE501136T1 (de) Imidazopyridinone
BRPI0917231A2 (pt) composição
BRPI0810557A2 (pt) composição
IT1392101B1 (it) Composizione comprendente isoflavoni
ATE514696T1 (de) Diphenyl-dihydro-imidazopyridinone
BRPI0811274A2 (pt) Composição
EP2043136A4 (en) FILMING COMPOSITION
FR2899479B1 (fr) Composition cicatrisante
BRPI0814519A2 (pt) Organopolissiloxano
BRPI0811451A2 (pt) Exopolissacarídeo
BRPI0812840A2 (pt) 2-imidazolinas
BRPI0812994A2 (pt) Microbiocidas
AT505058A3 (de) Türschliesssystem
BRPI0811002A2 (pt) Composição biofertilizante
BRPI0820960A2 (pt) composição

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ABIVAX (FR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/04/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF